Dipeptidyl peptidases 8 and 9: specificity and molecular characterization compared with dipeptidyl peptidase IV

被引:97
作者
Bjelke, Jais R.
Christensen, Jesper
Nielsen, Per F.
Branner, Sven
Kanstrup, Anders B.
Wagtmann, Nicolai
Rasmussen, Hanne B.
机构
[1] Novo Nordisk AS, Prot Struct & Biophys, DK-2880 Bagsvaerd, Denmark
[2] Biotech Res Innovat Ctr, DK-2100 Copenhagen O, Denmark
[3] Novo Nordisk AS, Med Chem, DK-2880 Bagsvaerd, Denmark
[4] Novo Nordisk AS, Prot Sci, DK-2880 Bagsvaerd, Denmark
[5] Novo Nordisk AS, Canc & Immunobiol, DK-2880 Bagsvaerd, Denmark
关键词
dipeptidyl peptidase; glucagon-like peptide; neuropeptide Y; peptide YY; S9b family; valine pyrrolidide;
D O I
10.1042/BJ20060079
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Dipeptidyl peptidases 8 and 9 have been identified as gene members of the S9b family of dipeptidyl peptidases. In the present paper, we report the characterization of recombinant dipeptidyl peptidases 8 and 9 using the baculovirus expression system. We have found that only the full-length variants of the two proteins can be expressed as active peptidases, which are 882 and 892 amino acids in length for dipeptidyl peptidase 8 and 9 respectively. We show further that the purified proteins are active dimers and that they show similar Michaelis-Menten kinetics and substrate specificity. Both cleave the peptide hormones glucagon-like peptide-1, glucagon-like peptide-2, neuropeptide Y and peptide YY with marked kinetic differences compared with dipeptidyl peptidase IV. Inhibition of dipeptidyl peptidases IV, 8 and 9 using the well-known dipeptidyl peptidase IV inhibitor valine pyrrolidide resulted in similar K-i values, indicating that this inhibitor is non-selective for any of the three dipeptidyl peptidases.
引用
收藏
页码:391 / 399
页数:9
相关论文
共 28 条
[1]   Cloning, expression and chromosomal localization of a novel human dipeptidyl peptidase (DPP) IV homolog, DPP8 [J].
Abbott, CA ;
Yu, DMT ;
Woollatt, E ;
Sutherland, GR ;
McCaughan, GW ;
Gorrell, MD .
EUROPEAN JOURNAL OF BIOCHEMISTRY, 2000, 267 (20) :6140-6150
[2]   Structural and kinetic analysis of the substrate specificity of human fibroblast activation protein α [J].
Aertgeerts, K ;
Levin, I ;
Shi, LH ;
Snell, GP ;
Jennings, A ;
Prasad, GS ;
Zhang, YM ;
Kraus, ML ;
Salakian, S ;
Sridhar, V ;
Wijnands, R ;
Tennant, MG .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2005, 280 (20) :19441-19444
[3]   Crystal structure of human dipeptidyl peptidase IV in complex with a decapeptide reveals details on substrate specificity and tetrahedral intermediate formation [J].
Aertgeerts, K ;
Ye, S ;
Tennant, MG ;
Kraus, ML ;
Rogers, J ;
Sang, BC ;
Skene, RJ ;
Webb, DR ;
Prasad, GS .
PROTEIN SCIENCE, 2004, 13 (02) :412-421
[4]   Dipeptidyl peptidase 9 has two forms, a broad tissue distribution, cytoplasmic localization and DPIV-like peptidase activity [J].
Ajami, K ;
Abbott, CA ;
McCaughan, GW ;
Gorrell, MD .
BIOCHIMICA ET BIOPHYSICA ACTA-GENE STRUCTURE AND EXPRESSION, 2004, 1679 (01) :18-28
[5]   Tyrosine 547 constitutes an essential part of the catalytic mechanism of dipeptidyl peptidase IV [J].
Bjelke, JR ;
Christensen, J ;
Branner, S ;
Wagtmann, N ;
Olsen, C ;
Kanstrup, AB ;
Rasmussen, HB .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2004, 279 (33) :34691-34697
[6]  
Christensen J, 1999, MOL CELL BIOL, V19, P7741
[7]   CD26, let it cut or cut it down [J].
De Meester, I ;
Korom, S ;
Van Damme, J ;
Scharpé, S .
IMMUNOLOGY TODAY, 1999, 20 (08) :367-375
[8]   Dipeptidyl peptidase IV inhibition potentiates the insulinotropic effect of glucagon-like peptide 1 in the anesthetized pig [J].
Deacon, CF ;
Hughes, TE ;
Holst, JJ .
DIABETES, 1998, 47 (05) :764-769
[9]   Potent and selective proline derived dipeptidyl peptidase IV inhibitors [J].
Edmondson, SD ;
Mastracchio, A ;
Beconi, M ;
Colwell, LF ;
Habulihaz, B ;
He, HB ;
Kumar, SJ ;
Leiting, B ;
Lyons, KA ;
Mao, A ;
Marsilio, F ;
Patel, RA ;
Wu, JK ;
Zhu, L ;
Thornberry, NA ;
Weber, AE ;
Parmee, ER .
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2004, 14 (20) :5151-5155
[10]   Dipeptidyl peptidase IV and related enzymes in cell biology and liver disorders [J].
Gorrell, MD .
CLINICAL SCIENCE, 2005, 108 (04) :277-292